AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - High Dose
Description: Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Vehicle
Description: Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
Study NCT04259632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: daily eating window restricted to 8 hours
Study NCT04259632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction (CR)
Description: 15% daily caloric deficient
Study NCT02015013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 microgram/kg daily for 5 days, Subcutaneous injection.
Study NCT02015013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: IV injection 0.24 mg/kg as a single dose, 11 hours prior to apheresis
Study NCT04482309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion
Study NCT03969563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: 8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
Study NCT03969563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education
Description: 8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
Study NCT04437342 — intervention group
Intervention type: OTHER
Intervention: PHQ-9 (Patient Health Questionnaire) Depression Scale
Description: 9 question questionnaire for assessment of depression
Study NCT04437342 — intervention group
Intervention type: OTHER
Intervention: GAD-7 (General Anxiety Disorder) scale
Description: 7 question questionnaire for assessment of General Anxiety Disorder
Study NCT04437342 — intervention group
Intervention type: OTHER
Intervention: 38 questions questionnaire
Description: 38 questions questionnaire
Study NCT04437342 — intervention group
Intervention type: OTHER
Intervention: EPDS (Edinburgh Postnatal Depression Scale)
Description: 10 questions scale for detection of postpartum depression
Study NCT01564433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: Electromechanical gait trainer
Description: The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
Study NCT01564433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Convetional control treatment
Description: The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
Study NCT04879420 — intervention group
Intervention type: DRUG
Intervention: Teriparatide
Description: Teriparatide dispensing claim is used as the reference group.
Study NCT04879420 — intervention group
Intervention type: DRUG
Intervention: Risedronate
Description: Risedronate dispensing claim is used as the exposure group.
Study NCT01607775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a PEEK-cage
Description: A commercially avaliable cuboid cervical cage will be implantet
Study NCT01607775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA-cage
Description: The in-house produced cervical cage will be implanted
Study NCT03603756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: a novel anti-PD-1 antibody
Study NCT03603756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a VEGFR-2 tyrosine kinase inhibitor
Study NCT03603756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection
Description: cytotoxic agent that binds to topoisomerase I
Study NCT03603756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: cytotoxic agent that prevent depolymerization of cellular microtubules
Study NCT03603756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: cytotoxic agent that cross-links and denatures strands of DNA
Study NCT01596647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Study NCT01596647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Study NCT01596647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Study NCT01596647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Study NCT01596647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: dovitinib, 5 days on / 2 days off dose schedule
Study NCT00084084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Description: 0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
Study NCT04541719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled remifentanil analgesia
Description: Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
Study NCT04541719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural analgesia
Description: Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
Study NCT02503579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training
Description: physical activity program, 30 minutes
Study NCT02672553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDWARDS INTUITY Valve System, Model 8300A
Description: To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
Study NCT02672553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stented Aortic Bioprostheses
Description: In comparison to control valves available on the market undergoing FS-AVR
Study NCT04641936 — intervention group
Intervention type: OTHER
Intervention: No intervention required
Description: No intervention required
Study NCT04489407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Remote Photoplethysmography (rPPG) vital sign acquisition
Description: Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
Study NCT04489407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Photoplethysmography (rPPG) vital sign acquisition
Description: Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
Study NCT02184728 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: End-tidal CO2(portable capnometer)
Description: End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
Study NCT01946165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1,000 mg by mouth daily for each 28 day cycle.
Study NCT01946165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth once daily for each 28 day cycle.
Study NCT01946165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth daily for each 28 day cycle.
Study NCT01946165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
Study NCT00655642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
Study NCT00655642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
Study NCT00655642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Description: 12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
Study NCT04367883 — intervention group
Intervention type: DRUG
Intervention: Antihistamine
Description: No intervention is performed. We propose an observational study.
Study NCT04367883 — intervention group
Intervention type: DRUG
Intervention: Amantadine
Description: No intervention is performed. We propose an observational study
Study NCT04367883 — intervention group
Intervention type: DRUG
Intervention: ACEI
Description: No intervention is performed. We propose an observational study.
Study NCT04367883 — intervention group
Intervention type: DRUG
Intervention: ARB
Description: No intervention is performed. We propose an observational study.
Study NCT04367883 — intervention group
Intervention type: OTHER
Intervention: Influenza vaccine and COVID
Description: No intervention is performed. We propose an observational study.
Study NCT02872909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulight (Ambicare Health)
Description: battery-operated low irradiance red light LED (skin cancer plaster)
Study NCT01912859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/physical activity intervention
Description: Nutrition/physical activity intervention
Study NCT01761643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SoC + iTab
Description: Text messaging reminders to improve adherence to PrEP
Study NCT04252963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MUCOLASE tablet (streptokinase • streptodornase)
Description: streptokinase • streptodornase 5mg
Study NCT04252963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of MUCOLASE tablet
Study NCT05948137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 FDOPA PET/CT
Description: Nuclear medicine imaging modalities
Study NCT02087670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: controlled, supervised exercise protocol
Description: exercise program within a cardiac rehabilitation program
Study NCT02087670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise protocol no supervised
Description: Exercise program at the community
Study NCT03128853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 and DCI Mini Sensor
Study NCT04186624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial-subdeltoid bursa corticosteroid injection
Description: 1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
Study NCT04186624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subacromial-subdeltoid bursa corticosteroid injection
Description: 1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
Study NCT02044653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
Study NCT02044653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
Study NCT02044653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
Study NCT02044653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP
Description: Each Group of Hemodialysis (n=30) will be administered NESP 30ug
Study NCT02044653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIRCERA
Description: Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
Study NCT01965314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation based training
Description: In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
Study NCT01965314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training
Description: Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
Study NCT01965314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional training
Description: Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
Study NCT02489240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 tablets
Description: 2000 IU vitamin D3 tablets were taken daily for 6 days
Study NCT02489240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2000 IU placebo tablets were taken daily for 6 days
Study NCT05409716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach
Description: Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.
Study NCT05409716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wristband TR band for hemostasis in cardiac procedure using radial approach
Description: Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
Study NCT03577379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Blood Fibrin Clot
Description: For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
Study NCT03108066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3795
Description: 800 mg twice daily (four 200 mg oral tablets twice daily)
Study NCT04726111 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specimens specific for the study
Description: Specimens (blood, umbilical cord, umbilical cord blood, placenta)
Study NCT02757625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Description: * 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~* 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state
Study NCT03571685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainable Early Episode Clinic Model of Care
Description: The first 8 weeks is the education phase. Participants attend classes every week for up to 6 hours. From 9 weeks to 10 months participants attend classes for 5 hours every other week. Based on individual progress. Participants can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
Study NCT02616198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EquiaFil G-coat
Description: The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
Study NCT02616198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EquiaFil Fuji Varnish
Description: The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
Study NCT02616198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Riva SC G-coat
Description: The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
Study NCT02616198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Riva SC Fuji Varnish
Description: The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
Study NCT02095197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone 80mg
Description: C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
Study NCT02095197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone 80mg
Description: C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.